Clinical Trial Search

Primary: Diagnostic Accuracy of Subharmonic Ultrasound Imaging Compared to Standard Ultrasound or Contrast Enhanced Magnetic Resonance Imaging (MRI) — 70; 56 percent accurate…

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: Incidence of Endometriosis of the Appendix — 23; 30 Participants — p=0.01

Primary: Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy — 31; 42; 45 Participants

Primary: Disease-free Survival — 64; 71; 70 percentage of participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Concordance Between Cytological Findings From Fallopian Tubes to Surgical Histology Results. — 42; 2 fallopian tubes

Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells

Primary: Completion Rate of 16 Prespecified Views — 19; 24 Participants

Primary: Overall Survival — 2.14; 2.00 years

Primary: Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement — .143; .959 Proportion of Cytuity Cell Samples

Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants

Primary: Percentage of Subjects in Each Ultrasound Group With Additional Testing — 63; 14 Participants

Primary: Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel — 40 mg

Primary: Proportion of Subjects Reporting AEs of Chronic Lower Abdominal and/or Pelvic Pain After Insertion of Essure System or After Laparoscopic Tubal Sterilization — 39; 28…

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation — -56.86; -77.72; -36.69; -66.84 percentage of serum AMH change

Primary: Efficacy Patient Level — 26.9 percentage of participants

Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009

Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…

Primary: PFS — 29.8 Months

Primary: Overall Survival Rate

Primary: Patients With All Positive Margins Correctly Identified With the Device — 5 Patients w/ all positives identified

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1

Primary: Combined Best Overall Response Rate Based on Investigator Assessment — 0; 12 percentage of participants

Primary: 6 Month Progression Free Survival — 0 Participants

Primary: Number of Participants With Bilateral Tubal Patency as Assessed by HSG-follicular — 9; 1 Participants — p=0.4795

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: The Negative Predictive Value (PVV) of MRI